11 research outputs found
The Maunakea Spectroscopic Explorer Book 2018
(Abridged) This is the Maunakea Spectroscopic Explorer 2018 book. It is
intended as a concise reference guide to all aspects of the scientific and
technical design of MSE, for the international astronomy and engineering
communities, and related agencies. The current version is a status report of
MSE's science goals and their practical implementation, following the System
Conceptual Design Review, held in January 2018. MSE is a planned 10-m class,
wide-field, optical and near-infrared facility, designed to enable
transformative science, while filling a critical missing gap in the emerging
international network of large-scale astronomical facilities. MSE is completely
dedicated to multi-object spectroscopy of samples of between thousands and
millions of astrophysical objects. It will lead the world in this arena, due to
its unique design capabilities: it will boast a large (11.25 m) aperture and
wide (1.52 sq. degree) field of view; it will have the capabilities to observe
at a wide range of spectral resolutions, from R2500 to R40,000, with massive
multiplexing (4332 spectra per exposure, with all spectral resolutions
available at all times), and an on-target observing efficiency of more than
80%. MSE will unveil the composition and dynamics of the faint Universe and is
designed to excel at precision studies of faint astrophysical phenomena. It
will also provide critical follow-up for multi-wavelength imaging surveys, such
as those of the Large Synoptic Survey Telescope, Gaia, Euclid, the Wide Field
Infrared Survey Telescope, the Square Kilometre Array, and the Next Generation
Very Large Array.Comment: 5 chapters, 160 pages, 107 figure
Changes in transcriptome after in vivo exposure to ionising radiation reveal a highly specialised liver response
International audiencePurpose: To identify transcriptional gene-networks involved in the early in vivo response of liver cells to radiation exposure and improve our understanding of the molecular processes responsible for tissue radiosensitivity.Materials and methods: Transcriptome variations of liver RNA samples were measured 3 hours post-irradiation using microarray technology. The results were confirmed and extended using real-time polymerase-chain-reaction (RT-PCR).Results: We identified quantitative changes in the expression of 126 genes, most of which were observed for the first time. We show that some modifications, such as the upregulation of the cyclin-dependent kinase inhibitor 1A (Cdkn1A) gene, persisted for at least two months after the initial exposure. Other genes regulated by the transformation-related protein 53 (Trp53/p53) such as Bcl2-associated X protein (Bax) or etoposide-induced-2.4 (Ei24/PIG8) were not upregulated. Grouping differentially expressed genes into functional categories revealed that the primary response of liver cells to radiation exposure was the enhancement of oxidoreductase activity and inhibition of cell proliferation, involving cell cycle progression and apoptosis-related genes.Conclusions: The data provides evidence of gene expression modifications associated with the hepatic response to radiation exposure. One of the main differences observed with radiation-sensitive tissues such as the spleen was cell proliferation. The comparison of our data with transcriptome modifications in different biological models enabled the identification of networks of genes that might be co-regulated. Overall, our expression data revealed genes and cellular pathways that might help to improve our understanding of the molecular basis underlying tissue radiosensitivity and to identify possible targets for novel therapeutic strategies
Validation of a new pediatric air-displacement plethysmograph for assessing body composition in infants
Recommended from our members
The Maunakea Spectroscopic Explorer Book 2018
(Abridged) This is the Maunakea Spectroscopic Explorer 2018 book. It is
intended as a concise reference guide to all aspects of the scientific and
technical design of MSE, for the international astronomy and engineering
communities, and related agencies. The current version is a status report of
MSE's science goals and their practical implementation, following the System
Conceptual Design Review, held in January 2018. MSE is a planned 10-m class,
wide-field, optical and near-infrared facility, designed to enable
transformative science, while filling a critical missing gap in the emerging
international network of large-scale astronomical facilities. MSE is completely
dedicated to multi-object spectroscopy of samples of between thousands and
millions of astrophysical objects. It will lead the world in this arena, due to
its unique design capabilities: it will boast a large (11.25 m) aperture and
wide (1.52 sq. degree) field of view; it will have the capabilities to observe
at a wide range of spectral resolutions, from R2500 to R40,000, with massive
multiplexing (4332 spectra per exposure, with all spectral resolutions
available at all times), and an on-target observing efficiency of more than
80%. MSE will unveil the composition and dynamics of the faint Universe and is
designed to excel at precision studies of faint astrophysical phenomena. It
will also provide critical follow-up for multi-wavelength imaging surveys, such
as those of the Large Synoptic Survey Telescope, Gaia, Euclid, the Wide Field
Infrared Survey Telescope, the Square Kilometre Array, and the Next Generation
Very Large Array
La conquête de la montagne : des premières occupations humaines à l’anthropisation du milieu
International audienc
Clinical manifestations of intermediate allele carriers in Huntington disease
Objective: There is controversy about the clinical consequences of intermediate alleles (IAs) in Huntington disease (HD). The main objective of this study was to establish the clinical manifestations of IA carriers for a prospective, international, European HD registry. Methods: We assessed a cohort of participants at risk with <36 CAG repeats of the huntingtin (HTT) gene. Outcome measures were the Unified Huntington's Disease Rating Scale (UHDRS) motor, cognitive, and behavior domains, Total Functional Capacity (TFC), and quality of life (Short Form-36 [SF-36]). This cohort was subdivided into IA carriers (27-35 CAG) and controls (<27 CAG) and younger vs older participants. IA carriers and controls were compared for sociodemographic, environmental, and outcome measures. We used regression analysis to estimate the association of age and CAG repeats on the UHDRS scores. Results: Of 12,190 participants, 657 (5.38%) with <36 CAG repeats were identified: 76 IA carriers (11.56%) and 581 controls (88.44%). After correcting for multiple comparisons, at baseline, we found no significant differences between IA carriers and controls for total UHDRS motor, SF-36, behavioral, cognitive, or TFC scores. However, older participants with IAs had higher chorea scores compared to controls (p 0.001). Linear regression analysis showed that aging was the most contributing factor to increased UHDRS motor scores (p 0.002). On the other hand, 1-year follow-up data analysis showed IA carriers had greater cognitive decline compared to controls (p 0.002). Conclusions: Although aging worsened the UHDRS scores independently of the genetic status, IAs might confer a late-onset abnormal motor and cognitive phenotype. These results might have important implications for genetic counseling. ClinicalTrials.gov identifier: NCT01590589
Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study
Background: People with Huntington's disease (HD) have been observed to have lower rates of cancers. Objective: To investigate the relationship between age of onset of HD, CAG repeat length, and cancer diagnosis. Methods: Data were obtained from the European Huntington's disease network REGISTRY study for 6540 subjects. Population cancer incidence was ascertained from the GLOBOCAN database to obtain standardised incidence ratios of cancers in the REGISTRY subjects. Results: 173/6528 HD REGISTRY subjects had had a cancer diagnosis. The age-standardised incidence rate of all cancers in the REGISTRY HD population was 0.26 (CI 0.22-0.30). Individual cancers showed a lower age-standardised incidence rate compared with the control population with prostate and colorectal cancers showing the lowest rates. There was no effect of CAG length on the likelihood of cancer, but a cancer diagnosis within the last year was associated with a greatly increased rate of HD onset (Hazard Ratio 18.94, p < 0.001). Conclusions: Cancer is less common than expected in the HD population, confirming previous reports. However, this does not appear to be related to CAG length in HTT. A recent diagnosis of cancer increases the risk of HD onset at any age, likely due to increased investigation following a cancer diagnosis
Clinical and genetic characteristics of late-onset Huntington's disease
Background: The frequency of late-onset Huntington's disease (>59 years) is assumed to be low and the clinical course milder. However, previous literature on late-onset disease is scarce and inconclusive. Objective: Our aim is to study clinical characteristics of late-onset compared to common-onset HD patients in a large cohort of HD patients from the Registry database. Methods: Participants with late- and common-onset (30–50 years)were compared for first clinical symptoms, disease progression, CAG repeat size and family history. Participants with a missing CAG repeat size, a repeat size of ≤35 or a UHDRS motor score of ≤5 were excluded. Results: Of 6007 eligible participants, 687 had late-onset (11.4%) and 3216 (53.5%) common-onset HD. Late-onset (n = 577) had significantly more gait and balance problems as first symptom compared to common-onset (n = 2408) (P <.001). Overall motor and cognitive performance (P <.001) were worse, however only disease motor progression was slower (coefficient, −0.58; SE 0.16; P <.001) compared to the common-onset group. Repeat size was significantly lower in the late-onset (n = 40.8; SD 1.6) compared to common-onset (n = 44.4; SD 2.8) (P <.001). Fewer late-onset patients (n = 451) had a positive family history compared to common-onset (n = 2940) (P <.001). Conclusions: Late-onset patients present more frequently with gait and balance problems as first symptom, and disease progression is not milder compared to common-onset HD patients apart from motor progression. The family history is likely to be negative, which might make diagnosing HD more difficult in this population. However, the balance and gait problems might be helpful in diagnosing HD in elderly patients